Risk preference mood spreads, temporarily recovering to the 0.04 million yen level for the first time in 3 months.

The Nikkei average rose for the fourth consecutive business day. It closed at 39,910.55 yen, up 304.75 yen (with an estimated volume of 1.8 billion 50 million shares traded). Following the rise of major stock price indices in the US market the previous day, the Nikkei average began trading near the 0.04 million yen mark for the first time in about three months since July 19th. Subsequently, amidst a sense of immediate achievement due to reaching this milestone, there was a mix of buying and selling, with a battle continuing around the 0.04 million yen mark. While the day ended with the closing at today's lowest price, it

Fisco JapanOct 15 02:59 ET

The Nikkei Average rose for the fourth day, temporarily recovering to the 40,000 yen level, but concerns arise due to the decline in Asian stocks etc.

On the 14th, the US stock market continued to rise. The Dow Jones Industrial Average closed at 43,065.22, up 201.36 points, and the Nasdaq closed at 18,502.69, up 159.75 points. Following speculation of a slight interest rate cut leading to selling pressure and buying driven by expectations of demand recovery against the backdrop of additional fiscal policies by the Chinese government, the market opened with mixed results. Subsequently, expectations for earnings of major companies provided support, pushing the market higher. Furthermore, the rise of semiconductor Nvidia pushed up the Nasdaq, leading to gains towards the end of the trading session.

Fisco JapanOct 15 02:32 ET

Chordia---Research and development of pipelines centered around CTX-712 for the fiscal year ending in August 2024 is progressing smoothly.

Chordia Therapeutics <190A> announced its financial results for the August 2024 period on the 11th. Operating revenue was N/A (business revenue of 2.5 billion yen in the previous period), operating loss was 1.801 billion yen (profit of 0.212 billion yen in the same period), ordinary loss was 1.824 billion yen (profit of 0.225 billion yen in the same period), and net loss for the period was 1.827 billion yen (profit of 0.223 billion yen in the same period). In the current fiscal year, the pipeline is centered around the CLK inhibitor drug CTX-712 (hereinafter referred to as CTX-712).

Fisco JapanOct 15 02:14 ET

Active and newly listed stocks during the morning session.

*JINS HD <3046> 6160 +1000, significant overshooting in the previous period leads to increased dividends. *Kosaido HD <7868> 575 +80, positive sentiment towards the significant increase in first quarter profit announcement. *TSI HD <3608> 1069 +133, viewed as a positive factor with the announcement of share buyback. *Marumae <6264> 1687 +199, impact strengthened by the outlook of significant profit increase for the current period. *Bic Camera <3048> 1721 +191, both previous period performance and current outlook exceed consensus expectations.

Fisco JapanOct 15 01:02 ET

Rakuten G, Asahi Kasei, etc. (additional) Rating

Downgrade - Bearish Code Stock Name Securities Company Former Changed After -------------------------------------------------- <3349> Cosmos Pharmaceuticals McCollie 'Out P' 'Neutral' Target Stock Price Changed Code Stock Name Securities Company Former Changed After -------------------------------------------------- <3349> Cosmos Pharmaceuticals

Fisco JapanOct 14 22:20 ET

10/15 [Strength and Weakness Materials]

[Bullish and bearish materials] Bullish materials - Nikkei Average is rising (39,605.80, +224.91) - dow jones industrial average is rising (43,065.22, +201.36) - NASDAQ Composite Index is rising (18,502.69, +159.75) - $1 = 149.70-80 yen - Chicago Nikkei futures are rising (40,095, +485 compared to Osaka) - SOX index is rising (5,432.21, +96.27) - VIX index is decreasing (19.70, -0.76) - Expectations for subdued inflation in the USA - Active self-company

Fisco JapanOct 14 20:08 ET